# Special Issue

## Cancer Metabolomics 2024

## Message from the Guest Editor

We welcome the submission of original research articles or review papers as contributions to this Special Issue of Metabolites dedicated to Cancer Metabolomics. The aim for this issue is to highlight innovative metabolomic approaches for fundamental and clinical research in cancerology. These include new achievements in metabolomics research in oncology that provide mechanistic information on model systems or involve translational and clinical studies on cancer patients. We encourage contributions that include cross-disciplinary research, large-scale data collection and analysis, or multi-omics studies for integrative medicine. Investigations of metabolic markers of risk, early markers of disease, and prognostic metabolites markers of the evolution of responses to cancer treatment will be highly relevant contributions to this Special Issue. New approaches based on mass spectrometry or nuclear magnetic resonance (NMR), as well as broader technological and analytical developments leading to future advances in the field of cancer metabolomics, are also very welcome.


## **Guest Editor**

Dr. Bénédicte Elena-Herrmann

Institute for Advanced Biosciences, University Grenoble Alpes/CNRS/INSERM, Grenoble, France

#### Deadline for manuscript submissions

closed (25 February 2025)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/187102

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





## Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

### Editor-in-Chief

#### Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

